Dalmore Capital
QuietEdinburgh, X0Biotechnology, Healthcare, TelecomLast fund filed March 2013
4 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Dalmore Capital Fund | March 2013 | $451M | $374M | 13 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
4 partners are named across this firm’s filings, 4 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Alistair Ray | Quiet | None listed | 0 | 0 |
Classified sectors of Dalmore Capital’s own portfolio companies, based on 3 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Dalmore Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
No other firm shares a filed board seat with Dalmore Capital yet. That is a gap in what we have read, not a claim that Dalmore Capital invests alone.
A shared board seat: a company where filings name a Dalmore Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
| John McDonogh | Quiet | None listed | 0 | 0 |
| John Murphy | Quiet | None listed | 23 | 0 |
| Michael Ryan | Quiet | None listed | 7 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.